In this series Prof. Carel le Roux invites a number of experts to explore with him the topic of obesity and its management in clinical practice. This includes whether there is enough evidence to justify treating it as a disease, the links between weight loss and the comorbidities of obesity, some of the latest clinical trial data, and whether our communication style can help to mitigate some of the bias and stigma experienced by people who are overweight.
After completing this educational activity, learners will be able to
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board/Speakers Bureau | Boehringer Ingelheim, Currax, Eli Lilly, GI Dynamics, Gila, Herbalife, Irish Life Health, Novo Nordisk, Johnson & Johnson, and Rhythm Pharma |
| Consultant | Keyron |
| Research/Grant Support | Anabio |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Consultant | Altimmune, Amgen, Boehringer Ingelheim, Gelesis, Gilead Sciences, Eli Lilly & Company, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Sidekick Health, Twenty30.health, Xeno Biosciences |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board/Speakers Bureau/Honoraria | Novo Nordisk |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board/Honoraria | Novo Nordisk |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Honorarium | Novo Nordisk, Rhythm, Ethicon, AstraZeneca |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board/Speakers Bureau | Novo Nordisk, Eli Lilly, Bausch Health Canada, Boehringer Ingelheim |
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board | Eli Lilly, Novo Nordisk, Pfizer |
| Speakers Bureau | PronoKal/Nestlé Health Sciences, Rhythm Pharmaceuticals |
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity.
Episode 1 - Addressing barriers to the management of obesity in primary care
This module was accredited on the 31 August 2023 and will expire on the 30 August 2024.
Episode 2 - Can weight loss improve the complications of obesity?
This module was accredited on 11 September 2023 and will expire on the 11 September 2024.
Episode 3 - Tackling stigma associated with obesity
This module was accredited on 3 October 2023 and will expire on the 3 October 2024.
Episode 4: Obesity Week 2023 Special - The Health Benefits of Weight Loss
This module was accredited on 30 October 2023 and will expire on the 30 October 2024.
Episode 5: Examining the Efficacy and Safety of Anti-Obesity Medications
This module was accredited on 29 November 2023 and will expire on the 29 November 2024.
Episode 6: What's Next in Anti-Obesity Medications and for Weight Management?
This module was accredited on 13 December 2023 and will expire on the 13 December 2024.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning (ACHL) designates each enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu
The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
In the final episode of this podcast series, Prof. Carel le Roux is joined by Prof. Luca Busetto to discuss the future of obesity care including new treatments and guideline recommendations.
Prof. Carel le Roux and Dr. Sean Wharton discuss the efficacy and safety of new treatments for obesity and explore why we have seen a shift in expectations from them.
Prof. Carel le Roux welcomes Prof. Alex Miras as they discuss recent publications on why losing weight can bring health benefits for people with obesity.
Join Prof. Carel le Roux and Joseph Nadglowski as they explore weight judgment, shame, and blame, and ask what we can do to tackle this stigma.
Join Prof. Carel le Roux and Dr. Michael Crotty as they investigate the link between obesity and its complications, and whether weight loss translates into improvements in these conditions.
Join Prof. Carel le Roux and Dr. Lee Kaplan as they discuss whether we should classify obesity as a lifestyle choice and so a risk factor for other diseases, or a disease in itself...